Early Angiotensin II in the Emergency Department

What Was Tested

The trial (phase 4) is built around Angiotensin II.

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED).

The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED.

It had 1 arm (groups): Angiotensin II Infusion (experimental).

The registry classes the interventions as drug.

More on the Plan

Following informed consent, patients will receive intravenous angiotensin II (AT-II) infusion for blood pressure support.

Who Took Part

The registry lists 20 planned participants were the target.

It was open to people of any sex aged from 18 years up to 99 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥18; and. Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and. Can provide written informed consent (or legally authorized representative).

The full record lists 4 inclusion and 8 exclusion criteria; among the exclusions: acute coronary syndrome;; cardiogenic shock;; patients with a history of mesenteric ischemia;.

How the Study Was Run

It was run as a non-randomized, single-group and open-label study.

Everyone knew when Angiotensin II was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-04-01 with completion listed for 2026-12-31.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Feasibility of completing all clinical trial activities (time frame: From enrollment to the end of treatment up to 6 hours after the angiotensin II infusion is initiated).

It also tracked 3 secondary outcomes, for example Mean arterial pressure response.

What This Means in Plain Language

Put simply, this is a phase 4, non-randomized trial of Angiotensin II in 20 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Angiotensin II compound page, all human trials.